At present, targeting of CD73 with Oleclumab is considered for combined radio-chemo-immunotherapy concepts to improve the survival of stage III unresectable NSCLC patients (COAST and PACIFIC-9 clinical trials) (Herbst et al., 2022; Barlesi et al., 2024). The gene discussed is NT5E; the disease is non-small cell lung carcinoma.